FDA authorizes Moderna coronavirus vaccine for emergency use across the US

FDA authorizes Moderna coronavirus vaccine for emergency use across the US

Moderna’s is the second Covid-19 vaccine to receive such approval, following Pfizer’s vaccine, which uses the same technology

The Moderna campus in Norwood, Massachusetts.

The Moderna campus in Norwood, Massachusetts. Photograph: Joseph Prezioso/AFP/Getty ImagesJessica Glenza@JessicaGlenzaFri 18 Dec 2020 19.51 EST

121

The Food and Drug Administration (FDA) has authorized a vaccine developed by Moderna and federal researchers, the second Covid-19 vaccine to receive such approval for emergency use across the US.

The vaccine’s emergency authorization brings the second drug to prevent Covid-19 to the American public within a week, and millions of doses are expected to begin immediate distribution to health workers and long-term care residents.

Moderna’s vaccine is 94% effective at preventing Covid-19, and is authorized in adults 18 and older. The authorization comes after it was recommended by an FDA advisory panel of independent experts.Pfizer vaccine: FDA says extra doses in vials can be used, potentially expanding US supplyRead more

“With the availability of two vaccines now for the prevention of Covid-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said Stephen Hahn, the FDA Commissioner, in a statement announcing the emergency authorization.Advertisementhttps://d6c2f17a00a005d898ccf38684e5bd04.safeframe.googlesyndication.com/safeframe/1-0-37/html/container.html

The vaccine developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) uses messenger RNA technology to introduce the body to the spike proteins coating the surface of the coronavirus.

“I would anticipate that we likely will see shots in the arm by the very early part of next week,” said Dr Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), to NBC earlier today.

Unlike the Pfizer vaccine, the Moderna vaccine deliveries will be managed by the federal government, using funding from Operation Warp Speed, the Trump administration’s program to quickly develop and disseminate Covid-19 vaccines and treatments.

Pfizer’s vaccine, the first to prevent Covid-19 authorized in the US last week, uses the same technology. Both companies are expected to apply for full approval for the vaccines in the coming months. Federal authorities hope to vaccinate 20 million people before the end of the year.

The authorization comes as the first doses of a vaccine developed by Pfizer are administered to health workers and longterm care residents, after it was authorized by the FDA last week.

Several high profile figures have already received the Pfizer vaccine, including the vice-president, Mike Pence, and the House speaker, Nancy Pelosi, on Friday. Joe Biden is due to receive his vaccine on Monday.

Moderna’s vaccine holds at least two distinct advantages over the first vaccine. It needs to be refrigerated, but does not require the ultra-cold -70C (-94F) required by Pfizer’s vaccine. That means the vaccine could be easier to transport in rural areas, and less susceptible to wastage. Further, Moderna’s data shows its vaccine appears to protect people against severe Covid-19, when it does not prevent the disease.

The authorization also comes as the virus continues to inflict a devastating toll on Americans. Thursday set a new record for daily deaths, when more than 3,500 Americans succumbed to the virus in one day.

viewpoint article published in the Journal of the American Medical Association the same week captured the toll: “The daily US mortality rate for Covid-19 deaths is equivalent to the September 11, 2001, attacks, which claimed 2,988 lives, occurring every 1.5 days, or 15 Airbus 320 jetliners, each carrying 150 passengers, crashing every day,” wrote Dr. Stephen Woolf and co-authors.

The authorization, a landmark achievement for modern medicine, is also a major achievement for Moderna. Prior to the authorization, the company had no products approved for use by the FDA. Prior to working on an mRNA vaccine for Covid-19, scientists at Moderna were researching mRNA technology primarily in cancers.

A doctor administer a Pfizer vaccine in Long Island, New York.
A doctor administer a Pfizer vaccine in Long Island, New York. Photograph: Brendan McDermid/Reuters

Moderna’s vaccine brings to 300 million the number of potential doses to be administered to high-risk populations, 200 million of which Moderna is contracted to provide to the federal government.

Because each vaccine requires a two-dose “booster” regimen, that means the US will have enough doses to immunize 150 million people, if it is able to effectively roll out one of the most ambitious immunization campaigns in the history of medicine. Moderna is relying primarily on subcontracted manufacturers to produce millions of doses of its vaccine.

Even with the monumental achievement of authorizing a second vaccine, scientists will still need to move forward on more vaccine candidates to provide the manufacturing capacity to reach another millions more Americans and people around the world.

That means the authorization of the second vaccine will not immediately bring about a return to normalcy, as it will take the better part of a year to immunize and distribute vaccinations to hundreds of millions of Americans.

Both shots will need to overcome high levels of vaccine hesitancy from a skeptical and weary American public, who for months have been bombarded by misinformation. Moderna’s vaccine may face an even higher hurdle, as the same White House which has disseminated Covid-19 misinformation played a role in its development.

The Moderna vaccine was found to be more than 94% effective at preventing Covid-19, in a trial of more than 30,000 patients. Moderna’s scientists said there were two allergic reactions in its trial, one in the placebo arm and another in a vaccine recipient.

In the vaccine arm, the allergic reaction was more than 60 days after the participant received the vaccine, and was found to be related to a separate medical procedure.$0contributions$1,250,000our goal

Since you’re here …

… we have a small favour to ask. Millions are flocking to the Guardian for open, independent, quality news every day. Readers in all 50 states and in 180 countries around the world now support us financially.

As we prepare for what promises to be a pivotal year for America, we’re asking you to consider a year-end gift to help fund our journalism.

Donald Trump’s presidency is ending, but America’s systemic challenges remain. From broken healthcare to corrosive racial inequality, from rapacious corporations to a climate crisis, the need for fact-based reporting that highlights injustice and offers solutions is as great as ever.

We believe everyone deserves access to information that’s grounded in science and truth, and analysis rooted in authority and integrity. That’s why we made a different choice: to keep our reporting open for all readers, regardless of where they live or what they can afford to pay. Powerful journalism drives change; this is some of the high-impact reporting that Guardian readers funded in 2020.

In these perilous times, an independent, global news organisation like the Guardian is essential. We have no shareholders or billionaire owner, meaning our journalism is free from commercial and political influence.

If there were ever a time to join us, it is now. Your funding powers our journalism. We’re asking readers to help us raise $1.25m to support our reporting in the new year. Every contribution, however big or small, will help us reach our goal. Make a gift now from as little as $1. Thank you.Support the GuardianRemind me late DecemberAccepted payment methods: Visa, Mastercard, American Express and PayPalTopics

Social media & sharing icons powered by UltimatelySocial
error

Enjoy this blog? Please spread the word :)

RSS
Follow by Email
LinkedIn
LinkedIn
Share
Scroll to Top